STUDIO LEGAL advises Freigeist on its investment in BioThrust

STUDIO LEGAL has advised Freigeist on its 7-digit investment in BioThrust.

With its bioreactors, BioThrust enables scalable and affordable stem cell therapies for previously untreatable diseases such as Parkinson's, Alzheimer's and spinal cord injuries. Through the novel bionic approach of the BioThrust reactors, the physiological conditions for the proliferation of stem cells can be created, thus enabling industrial production for the first time.

BioThrust will use the new capital to realize initial pilot projects and further build up the product development team.

Freigeist Capital was advised by André Eggert, Inez Nuding, Dr. Benedict Murke (all Venture Capital) and Maria Presser (IP).

Latest Insights